###
中国临床研究英文版:2026,39(10):1632-1636
View/Add Comment     过刊浏览    高级检索     
←前一篇   |   后一篇→
本文二维码信息
码上扫一扫!
脂质代谢调节药物治疗脓毒症的研究进展
(1. 中国人民解放军联勤保障部队第九○四医院药剂科,江苏 无锡 214000;2. 南京医科大学附属脑科医院南京市胸科医院心血管内科,江苏 南京 210029)
Research progress on lipid metabolism regulating drugs for the treatment of sepsis
摘要
本文已被:浏览 162次   下载 159次
Received:May 15, 2026   Published Online:October 23, 2026
中文摘要: 脓毒症是一种由感染引发的危及生命的综合征,其发病机制涉及免疫失调与代谢重编程的复杂相互作用,其中脂质代谢紊乱发挥重要作用。近年来研究表明,脓毒症患者常表现为三酰甘油升高,胆固醇尤其是高密度脂蛋白(HDL)水平降低,这些变化不仅反映疾病严重程度,也与炎症调控和内毒素清除过程相关。基于此,靶向脂质代谢的治疗策略逐渐受到关注,包括他汀类、贝特类、前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型(PCSK9)抑制剂、胆固醇酯转运蛋白(CETP)抑制剂以及重组HDL 和载脂蛋白AⅠ模拟肽等。尽管部分药物在实验研究中显示出抗炎和改善预后的潜力,但临床研究结果有限。未来研究需关注脂蛋白功能、疾病分期及患者异质性,并结合多组学与精准医学方法,以推动脂质代谢靶向治疗的临床转化。
Abstract:Sepsis is a life-threatening syndrome caused by infection ,characterized by a complex interplay between immune dysregulation and metabolic reprogramming,in which lipid metabolism plays a critical role. Recent studies have shown that patients sepsis commonly exhibit elevated triglyceride levels and reduced cholesterol levels,particularly high-density lipoprotein(HDL).These changes not only reflect disease severity,but are also related to the regulation of inflammation and endotoxin clearance. Based on these findings,therapeutic strategies targeting lipid metabolism have gained increasing attention,including statins,fibrates,proprotein convertase subtilisin/kexin type 9(PCSK9)inhibitors,cholesteryl ester transfer protein(CETP)inhibitors,as well as reconstituted HDL and apolipoprotein A Ⅰmimetic peptides. Although some of these agents have demonstrated anti-inflammatory effects and potential prognostic benefits in experimental studies,clinical evidence remains limited. Future research should focus on lipoprotein functionality,disease stage ,and patient heterogeneity ,and integrate multi-omics and precision medicine approaches to facilitate the clinical translation of lipid-targeted therapies in sepsis.
文章编号:     中图分类号:R631 R977    文献标志码:A
基金项目:江苏省中医药和中西医结合科研项目(CYTF2026048)
引用文本:


Scan with WeChat

Scan with WeChat